Veracyte officer receives new stock awards

Febbo Phillip G. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Febbo Phillip G. reported acquisition or exercise transactions in this Form 4 filing.

Veracyte, Inc. reported that Chief Scientific & Med Officer Phillip G. Febbo received equity awards in the form of common stock on March 6, 2026. He was granted 29,603 shares and an additional 6,578 shares, both at no cash cost to him.

According to the footnotes, the first award, structured as restricted stock units, vests 25% on March 2, 2027 and then 1/16 each quarter, subject to continued employment. The second award vests in full on the first anniversary of the grant date, also contingent on his continued employment. Following these grants, he directly owns 153,527 shares of Veracyte common stock.

Insider Trade Summary

Grant/Award: 36,181 shares

Grant/Award 2 txns

Insider Febbo Phillip G.

Role Chief Scientific & Med Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	29,603	$0.00	$0.00
Grant/Award	Common Stock	6,578	$0.00	$0.00

Holdings After Transaction: Common Stock — 153,527 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.
2. F2. Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Veracyte (VCYT) report for Phillip G. Febbo?

Veracyte reported that Chief Scientific & Med Officer Phillip G. Febbo received equity awards in common stock on March 6, 2026. These were compensation-related grants, not open-market purchases, and increase his direct ownership stake in the company.

How many Veracyte (VCYT) shares were granted to Phillip G. Febbo?

Phillip G. Febbo was granted 29,603 shares of common stock plus an additional 6,578 shares. Both grants were recorded at a price of $0.00 per share, reflecting compensation awards rather than cash purchases in the market.

What are the vesting terms of Phillip G. Febbo’s Veracyte (VCYT) stock awards?

One restricted stock unit award vests 25% on March 2, 2027, then 1/16 each quarter, subject to continued employment. The second award vests in full on the first anniversary of the March 6, 2026 grant date, also contingent on his continued employment.

Are Phillip G. Febbo’s Veracyte (VCYT) grants open-market purchases?

No, the transactions are coded as awards (Code A), meaning they are equity compensation grants, not open-market purchases. The shares were granted at a stated price of $0.00 per share and vest over time based on continued employment.

How many Veracyte (VCYT) shares does Phillip G. Febbo own after these grants?

After the reported grants, Phillip G. Febbo directly owns 153,527 shares of Veracyte common stock. This figure reflects his position following the two March 6, 2026 award transactions disclosed in the Form 4 filing.

Do Phillip G. Febbo’s Veracyte (VCYT) awards depend on continued employment?

Yes, both restricted stock unit awards require his continuing employment through each vesting date. One vests quarterly after March 2, 2027, while the other vests in full on the first anniversary of the March 6, 2026 grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 05:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Febbo Phillip G.

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific & Med Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A(1)		29,603	A	$0	146,949	D
Common Stock	03/06/2026		A(2)		6,578	A	$0	153,527	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

2. Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.